NASDAQ:BIIB - Biogen Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$332.03 -5.51 (-1.63 %)
(As of 01/17/2019 06:43 AM ET)
Previous Close$337.54
Today's Range$330.06 - $339.97
52-Week Range$249.17 - $388.67
Volume1.23 million shs
Average Volume1.28 million shs
Market Capitalization$68.01 billion
P/E Ratio15.22
Dividend YieldN/A
Beta0.99
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. In addition, the company is developing BAN2401, which has completed Phase II clinical trial for the treatment of Alzheimer's disease, as well as Elenbecestat that is in Phase III clinical trial for treatment of early Alzheimer's disease. The company's Phase II clinical trial products comprise Opicinumab for MS; BIIB092 for PSP; Natalizumab for Acute Ischemic Stroke and Epilepsy; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I/IIa clinical trial products consist of BIIB080 for patients with mild Alzheimer's disease. The company's Phase I clinical trial products comprise Aducanumab for Alzheimer's disease; BIIB076, an anti-tau monoclonal antibody; and BIIB054 for Parkinson's disease. Biogen Inc. offers products through its sales force and marketing groups. It has strategic collaboration with Ionis Pharmaceuticals to develop drug candidates for neurological diseases. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Receive BIIB News and Ratings via Email

Sign-up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BIIB
CUSIP09062X10
Phone617-679-2000

Debt

Current Ratio2.75
Quick Ratio2.46

Price-To-Earnings

Sales & Book Value

Annual Sales$12.27 billion
Price / Sales5.45
Cash Flow$26.6263 per share
Price / Cash Flow12.47
Book Value$59.56 per share
Price / Book5.57

Profitability

Net Income$2.54 billion
Net Margins24.08%
Return on Assets20.54%

Miscellaneous

Employees7,300
Market Cap$68.01 billion
OptionableOptionable

Biogen (NASDAQ:BIIB) Frequently Asked Questions

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

How were Biogen's earnings last quarter?

Biogen Inc (NASDAQ:BIIB) issued its quarterly earnings results on Tuesday, October, 23rd. The biotechnology company reported $7.40 earnings per share for the quarter, beating the Zacks' consensus estimate of $6.78 by $0.62. The biotechnology company had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.33 billion. Biogen had a net margin of 24.08% and a return on equity of 38.70%. Biogen's quarterly revenue was up 11.7% compared to the same quarter last year. During the same period last year, the company posted $6.31 EPS. View Biogen's Earnings History.

When is Biogen's next earnings date?

Biogen is scheduled to release their next quarterly earnings announcement on Tuesday, January 29th 2019. View Earnings Estimates for Biogen.

How can I listen to Biogen's earnings call?

Biogen will be holding an earnings conference call on Tuesday, January 29th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

What price target have analysts set for BIIB?

29 brokerages have issued twelve-month target prices for Biogen's shares. Their predictions range from $262.15 to $470.00. On average, they expect Biogen's stock price to reach $381.8574 in the next year. This suggests a possible upside of 15.0% from the stock's current price. View Analyst Price Targets for Biogen.

What is the consensus analysts' recommendation for Biogen?

29 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 7 hold ratings and 22 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biogen.

What are Wall Street analysts saying about Biogen stock?

Here are some recent quotes from research analysts about Biogen stock:
  • 1. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $400 12-month price target. Biogen hosted a webcast this morning to outline its strategy in multiple sclerosis (MS), focusing on the pipeline as well as lifecycle management for the $9B base business. We saw detailed commentary about specific lifecycle management plans as most important. We think BIIB098 could be another option for new patients or Tecfidera switches. Although investors remain focused on aducanumab, we think understanding long-term MS growth is of similar importance." (12/12/2018)
  • 2. Mizuho analysts commented, "We updated our model post the 2Q18 earnings call and BAN2401 data last week." (7/31/2018)
  • 3. HC Wainwright analysts commented, "Valuation and risks. Our PT of $363/share is based on a discounted cash flow analysis using a 10% discount rate and 2.5% growth rate, in line with the expected discount and growth parameters of a commercial multiproduct biotechnology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) a smaller than anticipated commercial opportunity due to market size, competition, and/or pricing." (7/9/2018)

Has Biogen been receiving favorable news coverage?

Media coverage about BIIB stock has been trending positive on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Biogen earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the immediate future.

Who are some of Biogen's key competitors?

Who are Biogen's key executives?

Biogen's management team includes the folowing people:
  • Mr. Michel Vounatsos, CEO & Director (Age 56)
  • Mr. Jeffrey D. Capello, Exec. VP & CFO (Age 53)
  • Ms. Susan H. Alexander, Exec. VP, Chief of Legal & Corp. Services and Corp. Sec. (Age 61)
  • Dr. Michael D. Ehlers, Exec. VP and Head of R&D (Age 49)
  • Dr. Paul F. McKenzie, Exec. VP of Pharmaceutical Operations & Technology (Age 52)

Who are Biogen's major shareholders?

Biogen's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Waverton Investment Management Ltd (0.15%), Factory Mutual Insurance Co. (0.08%), Saratoga Research & Investment Management (0.07%), Gateway Investment Advisers LLC (0.06%), DNB Asset Management AS (0.05%) and Retirement Systems of Alabama (0.05%). Company insiders that own Biogen stock include Alexander J Denner, Alfred Sandrock, Brian S Posner, Michael D Ehlers, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Institutional Ownership Trends for Biogen.

Which institutional investors are selling Biogen stock?

BIIB stock was sold by a variety of institutional investors in the last quarter, including Ferguson Wellman Capital Management Inc., Retirement Systems of Alabama, Factory Mutual Insurance Co., Gulf International Bank UK Ltd, Saratoga Research & Investment Management, Virtu Financial LLC, First Midwest Bank Trust Division and Legacy Private Trust Co.. Company insiders that have sold Biogen company stock in the last year include Alfred Sandrock and Michael D Ehlers. View Insider Buying and Selling for Biogen.

Which institutional investors are buying Biogen stock?

BIIB stock was bought by a variety of institutional investors in the last quarter, including Vigilant Capital Management LLC, DNB Asset Management AS, Gateway Investment Advisers LLC, Cullinan Associates Inc., Polianta Ltd, Waverton Investment Management Ltd, Fox Run Management L.L.C. and Cozad Asset Management Inc.. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.

How do I buy shares of Biogen?

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $332.03.

How big of a company is Biogen?

Biogen has a market capitalization of $68.01 billion and generates $12.27 billion in revenue each year. The biotechnology company earns $2.54 billion in net income (profit) each year or $21.81 on an earnings per share basis. Biogen employs 7,300 workers across the globe.

What is Biogen's official website?

The official website for Biogen is http://www.biogen.com.

How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000.


MarketBeat Community Rating for Biogen (NASDAQ BIIB)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  1,487 (Vote Outperform)
Underperform Votes:  849 (Vote Underperform)
Total Votes:  2,336
MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe BIIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIIB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2019 by MarketBeat.com Staff

Featured Article: Float

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel